Neuroharmonics raises £1.2m for ultrasound-based neurotechnology

Wearable ultrasound devices designed to non-invasively interface with the brain are the focus of a £1.2m funding round for Neuroharmonics Ltd. The London-based company is developing a neurotechnology platform that utilizes next-generation ultrasound to treat neurological and psychiatric conditions. By using precisely focused sound waves, the technology modulates specific brain circuits to provide therapeutic interventions for disorders such as depression and essential tremor.

Incorporated in 2024, Neuroharmonics was established by a founding team with backgrounds in ultrasound engineering and clinical neuroscience. The company aims to create a new paradigm for non-invasive brain-computer interaction. Its platform is designed to offer a safe method for neuromodulation, potentially serving as an alternative to existing treatments for millions of people affected by brain disorders.

Financial records for the period ending 30 June 2025 indicate the company recorded a £371.8k loss. During that financial year, the business had five employees. More recent figures show the headcount has grown to 11 staff members as the company continues its research and development activities in the biotechnology sector.

The current funding round, estimated at £1.2m, follows a share allotment in April 2026 (filed in May 2026). This capital is directed toward the development of the company's transcranial ultrasound technology. Neuroharmonics intends for its platform to become a standard for non-invasive neuromodulation and a foundation for future brain-computer interface applications.